tirzepatide weight loss trial results The SURMOUNT-MAINTAIN Phase 3b is testing if adults with obesity can maintain by continuing or reducing (vs placebo) after achieving on the highest dose. #Tirzepatide https://t.co/FHyoDXDEYv Tirzepatide restricts obesity-related tumor growth

Slowing down the digestive process keeps food in the stomach longer, which can help people eat less because they feel full for longer, but can also make them feel nauseous

This mechanism enhances focus, concentration, and physical performance

The marketing also makes bold claims like "Lose 27 lbs in 60 Days" that feel overly promotional

Oral GLP-1 medications may be a reasonable option for: Patients early in their weight loss journey Patients with mild to moderate weight loss goals Patients who strongly prefer to avoid injections They may be less ideal for: Patients who have had bariatric surgery Patients needing significant weight loss Patients who have not responded to oral medications in the past The decision is not just about preference